Comparative Pharmacology
Head-to-head clinical analysis: FLUOXETINE POSTPARTUM SAFETY versus KALEXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXETINE POSTPARTUM SAFETY versus KALEXATE.
Fluoxetine-Safety-Postpartum vs KALEXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
10 mg orally once daily.
None Documented
None Documented
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Category A/B
Category C
SSRI Antidepressant
SSRI Antidepressant